Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 201–300 of 1,004
Tumor-Associated Microbiome: Where Do We Stand?
Oliva, M., Mulet-Margalef, N., Ochoa-de-Olza, M., Napoli, S., Mas-Lloret, J., Laquente, B., Alemany, L., Duell, E. J., Nuciforo, P. G., & Moreno, V. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031446 · Cited by 66
Peiffer, L. B., White, J. R., Jones, C. B., Slottke, R., Ernst, S. E., Moran, A. E., Graff, J. N., & Sfanos, K. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100822 · Cited by 63
Nan, K., Zhong, Z., Yue, Y., Shen, Y., Zhang, H., Wang, Z., Zhuma, K., Yu, B., Fu, Y., Wang, L., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333020 · Cited by 69
“18 The gut microbiota produces amino acids that affect CRC progression.”
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
Integrating the gut microbiome and pharmacology
Verdegaal, A. A., & Goodman, A. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8357 · Cited by 71
Glioma and the gut–brain axis: opportunities and future perspectives
Dono, A., Nickles, J., Rodriguez-Armendariz, A. G., McFarland, B. C., Ajami, N. J., Ballester, L. Y., Wargo, J. A., & Esquenazi, Y. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac054 · Cited by 68
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 58
“Oral intake of inosine, together with IL12 secretion byDCs, has been shown to enhance the effectiveness of anti– CTLA-4 ICB against different tumors implanted inmice by promoting antitumoral T-cell activity (48).”
BackgroundEffects of gut microbiota on immune responses and immunotherapy in colorectal cancer
Hou, X., Zheng, Z., Wei, J., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030745 · Cited by 66
“investigated the efficacy of ICIs therapy in both AOM/DSS induced colitis-associated cancer and MC38 tumor-bearing models, they found that Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species—that significantly enhanced efficacy of anti-PD-L1 and anti-CTLA-4 (88).”
BackgroundMicrobiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 71
“100 This improvement happened through T-cell-specificadenosine2AreceptorA 2A Rsignaling(Figure1).”
BackgroundCrosstalk between circadian rhythms and the microbiota
Pearson, J. A., Wong, F. S., & Li, W. (2020) · Immunology · doi:10.1111/imm.13278 · Cited by 61
From germ-free to wild: modulating microbiome complexity to understand mucosal immunology
Thomson, C. A., Morgan, S., Ohland, C., & McCoy, K. D. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00562-3 · Cited by 62
“Our group also showed that monocolonization with Bifidobacterium pseudolongum, isolated from colorectal tumors following immune checkpoint blockade, increased the efficacy of anti-tumor immunotherapy.(75) B.”
BackgroundSelf-citationThe Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, Α. (2023) · Cancers · doi:10.3390/cancers15072101 · Cited by 76
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 68
“126 However, further research is needed to provide mechanistic insights into the potential roles of microbial-derived nucleosides in PDAC.”
BackgroundMicrobiota and Colorectal Cancer: From Gut to Bedside
Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 66
A Microbiota-Derived Metabolite Augments Cancer Immunotherapy Responses in Mice
Allen-Vercoe, E., & Coburn, B. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.005 · Cited by 57
Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet
Zhao, S., Peralta, R. M., Avina-Ochoa, N., Delgoffe, G. M., & Kaech, S. M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101485 · Cited by 66
Wu, H., Zheng, X., Pan, T., Yang, X., Chen, X., Zhang, B., Peng, L., & Xie, C. (2022) · International Journal of Cancer · doi:10.1002/ijc.34118 · Cited by 54
Hu, X., Xu, X., Zeng, X., Jin, R., Wang, S., Jiang, H., Tang, Y., Chen, G., Wei, J., Chen, T., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2221093 · Cited by 65
Gut microbiota: impacts on gastrointestinal cancer immunotherapy
Lau, H. C.-H., Sung, J. J. �., & Yu, J. Q. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1869504 · Cited by 59
“Of note, evidence on how metabolites could influence immunotherapy had been insufficient until recently, by which a study in 2020 identified that a metabolite called inosine (produced by Bifidobacterium pseudolongum) could enhance response to immune checkpoint blockade in mice through activating anticancer T cells.(14…”
BackgroundThe tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 65
Interactions between diet and gut microbiota in cancer
Nakatsu, G., Andreeva, N., MacDonald, M. H., & Garrett, W. S. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01736-4 · Cited by 67
Zhang, K., Xu, Y., Zheng, Y., Zhang, T., Wu, Y., Yan, Y., Yu, L., Cao, X., Wang, X., Yan, F., et al. (2024) · Advanced Science · doi:10.1002/advs.202406917 · Cited by 85
The microbiome(s) and cancer: know thy neighbor(s)
González‐Sánchez, P., & DeNicola, G. M. (2021) · The Journal of Pathology · doi:10.1002/path.5661 · Cited by 62
The role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 62
“The metabolite inosine produced by the microbiome has been shown to modulate the efficacy of cancer therapy without modulating the microbiome in murine models [42], which may be used as an adjuvant agent for various kinds of cancer therapy in the future.”
BackgroundBacterial‐Mediated Tumor Therapy: Old Treatment in a New Context
Liu, Y., Niu, L., Li, N., Wang, Y., Liu, M., Su, X., Bao, X., Yin, B., & Shen, S. (2023) · Advanced Science · doi:10.1002/advs.202205641 · Cited by 60
Akkermansia muciniphila: A potential target and pending issues for oncotherapy
Zhao, X., Zhao, J., Li, D., Yang, H., Chen, C., Qin, M., Wen, Z., He, Z., & Xu, L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106916 · Cited by 53
The Effects of Lactobacillus johnsonii on Diseases and Its Potential Applications
Zhang, Z., Zhao, L., Wu, J., Pan, Y., Zhao, G., Li, Z., & Zhang, L. (2023) · Microorganisms · doi:10.3390/microorganisms11102580 · Cited by 68
“With the rapid development of science and technology, L. johnsonii has also been recognized as having important applications in many fields such as biology, agriculture, animal hus-bandry [7], and medicine [8].”
BackgroundThe tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
“In the presence of exogenous IFN-γ and co-stimulatory signals from DCs, inosine promotes the differentiation of Th1 by binding to the adenosine A2A receptor (A2AR) on T cells, significantly increasing Th1 cell anti-tumor activity in CRC, melanoma, and bladder cancer [73].”
How microbiota improve immunotherapy
Ansaldo, E., & Belkaid, Y. (2021) · Science · doi:10.1126/science.abl3656 · Cited by 54
Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal Cancer
Chen, Y., & Chen, Y. (2021) · Cancers · doi:10.3390/cancers13164054 · Cited by 57
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 59
“…strategy for a wide range of cancers, understanding the mechanisms underlying tumor immunity and identifying biomarkers that predict patient outcomes has been a focus of cancer research (Rizvi et al, 2015; Kumagai et al, 2020a, 2020b; House et al, 2020; Mager et al, 2020; Smith et al, 2021).”
BackgroundLin, Y., Fan, L., Qi, Y., Xu, C., Jia, D., Jiang, Y., Chen, S., & Wang, L. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02746-6 · Cited by 58
“Bifidobacterium pseudolongum enhances the anti-CTLA-4 therapy response by producing the metabolite inosine [17].”
BackgroundThe danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“Inosine produced by Bifidobacterium pseudolongum binds to adenosine A 2A receptors, promoting the activation of antitumour T cells in the context of immunotherapy 166 , and also enhances the stemness of CAR T cells through its effects on the cellular metabolism 167 .”
Stagg, J., Golden, E. B., Wennerberg, E., & Demaria, S. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3015 · Cited by 55
“Intriguingly, inosine production by the gut microbiome has been shown to stimulate antitumor T cells via A2A receptors when sufficient costimulation is provided (65).”
BackgroundSelf-citationLu, S., Xu, J., Zhao, Z., Guo, Y., Zhang, H., Jurutka, P. W., Huang, D., Cao, C., & Cheng, S. (2023) · Food & Function · doi:10.1039/d3fo02018e · Cited by 58
Jiang, S., Ma, W., Ma, C., Zhang, Z., Zhang, W., & Zhang, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2341717 · Cited by 57
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
“in the gut facilitates enhanced ICI treatment efficacy through a mechanism that involves the increased systemic translocation (owing to ICI-induced decreased gut barrier function) of inosine and subsequent activation of anticancer T cells.(110) Considering the basic principles of immune activation and differentiation,…”
BackgroundTumor microbiome metabolism: A game changer in cancer development and therapy
Zhou, X., Kandalai, S., Hossain, F., & Zheng, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933407 · Cited by 57
Du, H., Shi, L. S., Wang, Q., Yan, T., Wang, Y., Zhang, X., Yang, C., Zhao, Y., & Yang, X. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04888 · Cited by 53
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 57
Microbiota-derived metabolites: Key modulators of cancer immunotherapies
Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 66
“55 TMAO has been implicated in enhancing ICI therapy.”
InfluentialHarness the functions of gut microbiome in tumorigenesis for cancer treatment
Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50
“pseudolongum), Lactobacillus johnsonii, and Olsenella, have been identified to positively impact the efficacy of immune checkpoint inhibitors in mouse cancer models [90].”
BackgroundSystemic Immunoregulatory Consequences of Gut Commensal Translocation
McPherson, A. C., Pandey, S. P., Bender, M. J., & Meisel, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.12.005 · Cited by 49
T cell metabolism in homeostasis and cancer immunity
Wei, J., Zheng, W., Chapman, N. M., Geiger, T. L., & Chi, H. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.02.003 · Cited by 59
“in vitro [38], and inosine can promote effector T cell expansion and function in the TME [38,39].”
BackgroundZhang, S., Cheng, L.-S., Zhang, Z., Sun, H., & Li, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106633 · Cited by 57
Fang, W., Peng, W., Qi, W., Zhang, J., Song, G., Pang, S., & Wang, Y. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105919 · Cited by 50
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Song, Y., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0394 · Cited by 78
A purine metabolic checkpoint that prevents autoimmunity and autoinflammation
Saveljeva, S., Sewell, G. W., Ramshorn, K., Cader, M. Z., West, J. A., Clare, S., Haag, L.-M., Rodrigues, R. P. D. A., Unger, L. W., Iglesias-Romero, A. B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.009 · Cited by 57
“The intestinal microbiota may also affect inosine plasma levels (Mager et al., 2020).”
BackgroundMicrobiota alters the metabolome in an age- and sex- dependent manner in mice
Brown, K., Thomson, C. A., Wacker, S., Drikic, M., Groves, R., Fan, V., Lewis, I. A., & McCoy, K. D. (2023) · Nature Communications · doi:10.1038/s41467-023-37055-1 · Cited by 49
Self-citationGut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses
Sardar, P., Beresford-Jones, B. S., Xia, W., Shabana, O., Suyama, S., Ramos, R. J. F., Soderholm, A. T., Tourlomousis, P., Kuo, P., Evans, A. C., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01930-y · Cited by 49
“Other microbiota-derived metabolites, including Bifidobacterium inosine 26 , Enterococcus muropeptides 27 and bacterial flagellin 28 , have also been implicated in modulating ICI treatment response.”
Zhu, Y., Wang, X., Zhu, L., Tu, Y., Chen, W., Gong, L., Pan, T., Lin, H., Lin, J., Sun, H., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115923 · Cited by 55
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
Effect of gut flora mediated‐bile acid metabolism on intestinal immune microenvironment
Zhang, Y., Gao, X., Gao, S., Liu, Y., Wang, W., Feng, Y., Pei, L., Sun, Z., Liu, L., & Wang, C. (2023) · Immunology · doi:10.1111/imm.13672 · Cited by 53
“L. F. Mager et al. found that intestinal Bifidobacterium pseudolon-gum enhances immunotherapy response by inosine, which needs T cell to express adenosine A 2A receptor and requires costimulation [40].”
The role of gut microbial metabolites in the T cell lifecycle
Tran, M. T., Huh, J. R., & Devlin, A. S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02227-2 · Cited by 61
“Additionally, activation of the adenosine A2 A receptor (A2 A R)–cyclic AMP–protein kinase A (PKA) signaling cascade in T cells by bacterial inosine production induces T H 1 cell differentiation 68 (Table 1).”
Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy
Luo, W., Li, R., Pan, C., & Luo, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1710880 · Cited by 58
Yang, J., Zhang, Z., Xie, Z., Bai, L., Xiong, P., Chen, F., Zhu, T., Peng, Q., Wu, H., Zhou, Y. C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112837 · Cited by 53
Role of the microbiome in oral cancer occurrence, progression and therapy
Li, Z., Liu, Y., & Zhang, L. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105638 · Cited by 55
Stachyose modulates gut microbiota and alleviates DSS-induced ulcerative colitis in mice
Wang, C., Bai, J., Wang, B., Yu, L., Tian, F., Zhao, J., Zhang, H., Suo, H., Chen, W., & Zhai, Q. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.03.041 · Cited by 50
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
“Moreover, Mager et al. 272 reported that inosine, an immunotherapy-promoting metabolite produced by Bifido-bacterium pseudolongum , could promote T H 1 activation and enhance checkpoint inhibitor immunotherapy, with potential to be exploited to develop microbial-based adjuvant therapies.”
BackgroundXia, L., Zhu, X., Wang, Y., & Lü, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217123 · Cited by 56
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 66
“Beyond the harmful effects of lactic acid-induced acidosis, elevated levels of pH-neutral lactate can dampen cytotoxic T and NK cell effector functions through downregulation of NFAT and reduced expression of crucial effector proteins such as IFNγ 158,159 (Fig.”
InfluentialMicrobiome-based disease prediction with multimodal variational information bottlenecks
Grazioli, F., Siarheyeu, R., Alqassem, I., Henschel, A., Pileggi, G., & Meiser, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010050 · Cited by 53
Qu, Y., Dunn, Z. S., Chen, X., MacMullan, M. A., Cinay, G. E., Wang, H.-Y., Liu, J., Hu, F., & Wang, P. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.050 · Cited by 50
“65,66 Interestingly, inosine has a unique signaling bias upon A 2A R binding, favoring the ERK1/2 pathway to PKA stimulation, and, relative to adenosine, inosine is approximately four orders of magnitude less potent at A 2A R (EC50 300 l M vs. 6 nM), 67,68 which may account for its differing effect…”
Zhu, H., Xie, D., Wang, Y. X., Huang, R., Chen, X., Yang, Y., Wang, B., Peng, Y., Wang, J., Xiao, D., et al. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.11.005 · Cited by 64
“In our study, a non-enlarged splenic weight but higher CD8 + T cell infiltration in both xenograft tumor models might indicate activation of the immune response towards tumor eradication after FLASH-RT, as the splenic immune response also plays an important role in anti-tumor treatment [35].”
BackgroundLu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
Xu, Z., Zhu, W., Xu, D., Amevor, F. K., Wu, Y., Ma, D., Cao, X., Wei, S., Shu, G., & Zhao, X. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104355 · Cited by 50
“At the genus level, curcumin signi fi cantly modulates Bi fi dobacterium and Olsenella populations, promoting intestinal digestion, absorption, immune function, and antioxidant capacity (Engevik et al., 2019; Mager et al., 2020).”
BackgroundGut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Yan, J., Yang, L., Ren, Q., Zhu, C., Du, H., Wang, Z., Qi, Y., Xian, X., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471273 · Cited by 56
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
“In various mouse models, the generation of inosine by Bifido-bacterium pseudolongum activates CD8 + T cells and enhances the antitumour activity of ICIs 114 .”
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
“With IFN-γ co-stimulation and A₂A-receptor engagement, inosine can support Th1 differentiation and potentiate CTLA-4/PD-L1 blockade in murine tumors [24].”
InfluentialBacteria-based immune therapies for cancer treatment
Howell, L. M., & Forbes, N. S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.006 · Cited by 48
Small molecules in the big picture of gut microbiome-host cross-talk
Ma, Y., Liu, X., & Wang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104085 · Cited by 53
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“…immune cells and induce innate or adaptive immune responses; (b) metabolites produced by bacteria, such as SCFAs [109, 132, 133], ino-sine [134], peptidoglycan [127], trimethylamine N -oxide (TMAO) [135, 136], neurotransmitters (including dopamine, norepinephrine, serotonin, or…”
BackgroundWadan, A.-H. S., El‐Aziz, M. K. A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04155-2 · Cited by 60
“Beyond gastrointestinal complications, GMMs have the potential to modulate immune responses, thereby mitigating immune-related adverse events (irAEs) associated with immunotherapy, such as colitis and hepatitis (Mager et al. 2020).”
Singh, H., Balusamy, S. R., Sukweenadhi, J., Saravanan, M., Mohanprasanth, A., Mijakovic̀, I., & Singh, P. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03712-4 · Cited by 50
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy
Situ, Y., Zhang, P., Zhang, C., Jiang, A., Zhang, N., Zhu, L., Mou, W., Liu, Z., Wong, H. Z. H., Zhang, J., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105708 · Cited by 45
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 48
Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 50
Wu, J., Dong, W., Pan, Y., Wang, J., Wu, M., & Yu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296783 · Cited by 52
Improvement of inflammatory bowel disease by lactic acid bacteria-derived metabolites: a review
Guo, W., Mao, B., Tang, X., Zhang, Q., Zhao, J., Zhang, H., Chen, W., & Cui, S. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2291188 · Cited by 47
“(Mager et al. 2020).”
Then, C. K., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S. M., Bremner, D. M., Roberts, K. S., Smith, E. E., Heidari, Z., et al. (2024) · Microbiome · doi:10.1186/s40168-024-01804-1 · Cited by 52
“Furthermore, our discovery metabolomics analysis showed that psyllium plus inulin increased the level of caecal inosine as has previously been shown to enhance immunotherapy efficacy via activation of cytotoxic T cells [15, 39].”
BackgroundT cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 55
Gut microbial metabolites: Shaping future diagnosis and treatment against gastrointestinal cancer
Gou, H., Zeng, R., Lau, H. C.-H., & Yu, J. Q. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107373 · Cited by 51
De-coding the complex role of microbial metabolites in cancer
Escriva, P. P., Bernardino, C. C. T., & Letellier, E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115358 · Cited by 54
Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
Liu, W., Wang, Y., Luo, J., Liu, M., & Luo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586760 · Cited by 50
“Recent evidence has identified inosine as a key bacterial-derived metabolite acting through T cell-specific A2AR signaling to promote Th1 cell activation in a contextdependent manner (48).”
BackgroundShaikh, F. Y., White, J. R., Gills, J. J., Hakozaki, T., Richard, C., Routy, B., Okuma, Y., Usyk, M., Pandey, A., Weber, J. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4834 · Cited by 44
“Given an expanding knowledge of the microbiome’s impact (and specific microbes) on normal immune system development and in drug action, the hypothesis that therapeutic tumor responses associate with specific microbiota warrants further investigation (11, 12).”
BackgroundSimotang Alleviates the Gastrointestinal Side Effects of Chemotherapy by Altering Gut Microbiota
Deng, L., Zhou, X., Lan, Z., Tang, K., Zhu, X.-X., Mo, X., Zhao, Z., Zhao, Z., & Wu, M.-S. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2110.10018 · Cited by 45
“Olsenella and Faecalibaculum have also been reported to be two anticancer bacteria species that can improve tumor treatment effects [42, 43].”
BackgroundInteraction between microbiota and immunity and its implication in colorectal cancer
Xing, C., Du, Y., Duan, T., Nim, K., Chu, J., Wang, H. Y., & Wang, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963819 · Cited by 51
Cao, Q., Zhao, M., Su, Y., Liu, S., Lin, Y., Da, H., Yue, C., Liu, Y., Jing, D., Zhao, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-22-3705 · Cited by 55
Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents
Giurini, E. F., Godla, A., & Gupta, K. H. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-023-00715-x · Cited by 50
Rebeck, O. N., Wallace, M. J., Prusa, J., Ning, J., Evbuomwan, E. M., Rengarajan, S., Habimana-Griffin, L., Kwak, S., Zahrah, D., Tung, J., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.013 · Cited by 49
“45 Tumors in the distal SI and colon were enumerated and normalized to PBS tumor counts within each trial to evaluate the therapeutic efficacy of Sb _haPD-1.”
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors
Wu, Z., Wu, Q., Han, Y., Xiang, S.-J., Wang, Y., Wu, W.-W., Chen, Y., Feng, Z., Wang, Y.-Y., Xu, Z.-G., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.002 · Cited by 50
Zhang, F., Ferrero, M., Dong, N., D’Auria, G., Reyes-Prieto, M., Herreros-Pomares, A., Calabuig-Fariñas, S., Duréndez, E., Aparisi, F., Blasco, A., et al. (2021) · Cancers · doi:10.3390/cancers13112514 · Cited by 43
“Moreover, microbiota-derived end product metabolites from dietary fermentation, such as short-chain fatty acids (SCFAs), have been confirmed to influence the ICB clinical outcome by regulating the immune response [38,39].”
BackgroundThe triple interactions between gut microbiota, mycobiota and host immunity
Yang, J., Yang, H., & Li, Y. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2094888 · Cited by 49
“…Bifidobacterium pseudo-longum , Lactobacillus johnsonii , and Olsenella species were isolated in high abundance, with B. pseudolongum affecting the T cell expression of adenosine A2A receptor by secreting inosine, thereby significantly enhancing the response to immunotherapy (Mager et al. 2020).”
BackgroundLiu, N., Chen, L., Yan, M., Tao, Q., Wu, J., Chen, J., Chen, X., Zhang, W., & Peng, C. (2023) · Research · doi:10.34133/research.0127 · Cited by 41
“(3) For metabolite regulation, Bifidobacterium pseudolongumderived inosine increased the efficacy of ICIs in colon cancer by acting on inosine 2A receptors on T cells to enhance the antitumor immune response [40].”
BackgroundInterplay between Phytochemicals and the Colonic Microbiota
Kwon, C., Ediriweera, M. K., & Cho, S. K. (2023) · Nutrients · doi:10.3390/nu15081989 · Cited by 48
“Inosine, a colonic microbial metabolite of adenosine, enhanced the mucosal barrier in a colitis model and exhibited antitumor activity in several cancer models [86,87].”
BackgroundSalivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
de Medeiros, M. C., The, S., Bellile, E. L., Russo, N., Schmitd, L. B., Danella, E. B., Singh, P. A., Banerjee, R., Bassis, C. M., Murphy, G. R., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01677-w · Cited by 50
“Since microbial metabolites can affect response to therapy [50], PICRUSt was performed to predict functional pathways inferred from 16 s rRNA sequences that could potentially be associated with response.”
Method
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.